REGULATORY

MHLW Revises Guidance on Pediatric Development Plans under Amended PMD Act

March 3, 2026

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

Japan’s Ministry of Health, Labor and Welfare (MHLW) has issued a revised notification on the preparation of pediatric drug development plans ahead of the May 1 enforcement of the amended Pharmaceuticals and Medical Devices (PMD) Act. The updated guidance, sent…

To read the full story

MHLW Issues 15 Notices Ahead of PMD Act Amendment
March 2, 2026

REGULATORY

Pharma Wages Multi-Front Lobbying amid Push for Leaner Honebuto
June 12, 2026
Many Approved AGs Remain Unlisted Despite Final Pre-Reform Opportunity
June 12, 2026
iPark CEO Calls for National AI Drug Discovery Platform at LDP Hearing
June 12, 2026
MHLW Official Urges Proper IRB Selection under New GCP Rules
June 12, 2026
MHLW Panel Weighs Single IRB, DCT Metrics in Core Hospital Overhaul
June 12, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

20 Years at a Glance: Overseas Sales Surge at Japan Pharma, but R&D Investments Lag

By Hayate Horiguchi

Japan’s pharmaceutical industry has become a global business over the past two decades. Overseas markets now make up nearly three-quarters…

COLUMN

The Patient North Star: How Gilead Japan Redefined Innovation

By Philip Carrigan

In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…